home All News open_in_new Full Article

Health Canada Authorizes 4Moving Biotech to Launch Phase 2a INFLAM MOTION Clinical Trial for Knee Osteoarthritis

Health Canada’s approval enables 4Moving Biotech to initiate the INFLAM MOTION Phase 2a clinical trial The INFLAM MOTION trial serves as a proof-of-concept study for 4Moving Biotech’s flagship 4P004 program LILLE & PARIS, France — 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatment that modify the natural history of knee osteoarthritis, […]


today 7 d. ago attach_file Culture

attach_file Other
attach_file Science
attach_file Economics
attach_file Science
attach_file Science
attach_file Culture
attach_file Science
attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Science
attach_file Economics
attach_file Other
attach_file Science
attach_file Politics
attach_file Economics
attach_file Science
attach_file Science


ID: 1697644021
Add Watch Country

arrow_drop_down